These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 33528040)
21. A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation. Tan YH; Groom KM Aust N Z J Obstet Gynaecol; 2015 Feb; 55(1):90-3. PubMed ID: 25307153 [TBL] [Abstract][Full Text] [Related]
22. Magnesium sulphate for women at term for neuroprotection of the fetus. Nguyen TM; Crowther CA; Wilkinson D; Bain E Cochrane Database Syst Rev; 2013 Feb; (2):CD009395. PubMed ID: 23450601 [TBL] [Abstract][Full Text] [Related]
24. [Neuroprotection for preterm infants with antenatal magnesium sulphate]. Marret S; Ancel PY J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1418-1433. PubMed ID: 28166926 [TBL] [Abstract][Full Text] [Related]
25. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. De Silva DA; Synnes AR; von Dadelszen P; Lee T; Bone JN; ; Magee LA Implement Sci; 2018 Jan; 13(1):8. PubMed ID: 29325592 [TBL] [Abstract][Full Text] [Related]
31. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. Wolf HT; Huusom LD; Henriksen TB; Hegaard HK; Brok J; Pinborg A BJOG; 2020 Sep; 127(10):1180-1188. PubMed ID: 32237069 [TBL] [Abstract][Full Text] [Related]
32. Neurodevelopmental outcome at 2 years for preterm children born at 22 to 34 weeks' gestation in France in 2011: EPIPAGE-2 cohort study. Pierrat V; Marchand-Martin L; Arnaud C; Kaminski M; Resche-Rigon M; Lebeaux C; Bodeau-Livinec F; Morgan AS; Goffinet F; Marret S; Ancel PY; BMJ; 2017 Aug; 358():j3448. PubMed ID: 28814566 [No Abstract] [Full Text] [Related]
33. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. Kamyar M; Manuck TA; Stoddard GJ; Varner MW; Clark E BJOG; 2016 Jun; 123(7):1161-6. PubMed ID: 26036660 [TBL] [Abstract][Full Text] [Related]
34. [Gynecology/Obstetrics. Magnesium sulfate for fetal neuroprotection in preterm delivery. Latest advances in contraception.]. Irion O; Julen O; Dubuisson JB; Yaron M; Lourenço AG Rev Med Suisse; 2011 Jan; 7(278):117-20. PubMed ID: 21400942 [TBL] [Abstract][Full Text] [Related]
35. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Grether JK; Hoogstrate J; Walsh-Greene E; Nelson KB Am J Obstet Gynecol; 2000 Sep; 183(3):717-25. PubMed ID: 10992199 [TBL] [Abstract][Full Text] [Related]
36. Protection of brain development by antenatal magnesium sulphate for infants born preterm. Chollat C; Sentilhes L; Marret S Dev Med Child Neurol; 2019 Jan; 61(1):25-30. PubMed ID: 30294845 [TBL] [Abstract][Full Text] [Related]
37. Re: Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial: At which gestational ages should magnesium sulphate be given to women at risk of preterm birth? Larsen ML; Krebs L; Rackauskaite G; Hoei-Hansen CE; Greisen G BJOG; 2020 Sep; 127(10):1295-1296. PubMed ID: 32394601 [No Abstract] [Full Text] [Related]
38. Neuroprotective effect of magnesium sulfate in premature infants. Analysis after establishing an antenatal administration protocol in a tertiary care hospital. Fernández Monteagudo B; Villar Castro S; Carrascosa García P; Zeballos Sarrato S; Sánchez Luna M An Pediatr (Engl Ed); 2023 Oct; 99(4):224-231. PubMed ID: 37741767 [TBL] [Abstract][Full Text] [Related]
39. Influence of antenatal magnesium sulfate application on cord blood levels of brain-derived neurotrophic factor in premature infants. Bachnas MA; Mose JC; Effendi JS; Andonotopo W J Perinat Med; 2014 Jan; 42(1):129-34. PubMed ID: 24062546 [TBL] [Abstract][Full Text] [Related]
40. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. Bickford CD; Magee LA; Mitton C; Kruse M; Synnes AR; Sawchuck D; Basso M; Senikas VM; von Dadelszen P; BMC Health Serv Res; 2013 Dec; 13():527. PubMed ID: 24350635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]